Evidence map›Paper›PMID 42626968›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

A combined artificial intelligence-wet lab approach identifies a pivotal role of the NAD

Sofie Lautrup, Shu-Qin Cao, Xi Long, Bonnie Hei Man Liu, Beatriz Escobar-Doncel, Aristide Ferrante, Johannes Frank, Tomas Schmauck-Medina, Geoffrey Ho Duen Leung, Kristina Xiao Liang and 6 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sofie LautrupDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Shu-Qin CaoDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Xi LongHong Kong Science and Technology Park, Insilico Medicine Hong Kong Ltd., New Territories, Hong Kong, China.
Bonnie Hei Man LiuHong Kong Science and Technology Park, Insilico Medicine Hong Kong Ltd., New Territories, Hong Kong, China.
Beatriz Escobar-DoncelDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Aristide FerranteDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Johannes FrankDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Tomas Schmauck-MedinaDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Geoffrey Ho Duen LeungHong Kong Science and Technology Park, Insilico Medicine Hong Kong Ltd., New Territories, Hong Kong, China.
Kristina Xiao LiangDepartment of Biomedicine (IBM), University of Bergen, Bergen, Norway.
Ning LuDepartment of Biomedicine (IBM), University of Bergen, Bergen, Norway.
Katerina VeverovaMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Martin VyhnalekMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Frank W PunHong Kong Science and Technology Park, Insilico Medicine Hong Kong Ltd., New Territories, Hong Kong, China.
Alex ZhavoronkovHong Kong Science and Technology Park, Insilico Medicine Hong Kong Ltd., New Territories, Hong Kong, China.
Evandro Fei FangDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.ORCID https://orcid.org/0000-0003-0355-7202

Funding

Akershus University Hospital #261973Akershus University Hospital #262960Akershus University Hospital #269901Alzheimer's Association PTC-Gene-25-1439553Civitan Norges Forskningsfond #281931Cure Alzheimer's Fund #282952Cure Alzheimer's Fund #284930Czech Ministry of Health project #NW26-04-00501Czech Republic-Norway KAPPA programme #TO01000215Ellcome Leap's Dynamic Resilience Program (jointly funded by Temasek Trust) #104617HORIZON-TMA-MSCA-DN #101073251National Natural Science Foundation of China #81971327NordForsk Foundation #119986Norwegian Health Association #281956Norwegian Health Association #43622Research Council of Norway #262175Research Council of Norway #334361the Rosa sløyfe/Norwegian Cancer Society and Norwegian Breast Cancer Society #207819The South-Eastern Norway Regional Health Authority (Helse Sør-øst RHF) #2020001The South-Eastern Norway Regional Health Authority (Helse Sør-øst RHF) #2021021The South-Eastern Norway Regional Health Authority (Helse Sør-øst RHF) #2023093Wellcome Trust
6 · The paper itself

Abstract

introductionEmerging evidence points to a role of nicotinamide mononucleotide (NAD

methodsWe analyzed transcriptomic data from 12 human brain regions across 77 integrated public datasets spanning major neurodegenerative diseases and controls to assess NAD

resultsThe NAD DISCUSSION: Our study combines artificial intelligence-driven and experimental approaches to identify novel targets for neurodegeneration, revealing disruption of the NAD

Indexed as

AgingArtificial IntelligenceBrainMitophagyNADNeurodegenerative DiseasesAlzheimer DiseaseAnimalsCaenorhabditis elegansHumansInduced Pluripotent Stem CellsNeuronsNADADagingALSartificial intelligenceHDmachine learningmitophagyNAD+PandaOmicsPD

Identifiers

PMID42626968
PMCPMC13495064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.